Sanofi 주식 가격. SAN - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

가격

104.36

매수가

104.00

매도가

104.50

거래량

2,844,567

103.18 일간 변동폭 104.46

85.07 52주 범위 106.14

market_cap

130.726B

전일 종가

104.84

개장가

103.82

최근 거래 시간

260

104.36

마지막 거래 시간

재정 규모

VWAP

평균 볼륨(3m)

1,663,631

발행 주식

1,252,640,466

배당수익률

10.62%

주가수익률

23.51

주당순이익(EPS)

4.44

매출

46.11B

순이익

5.56B

섹터

Health & Allied Services,nec

산업

Pharmaceutical Preparations

웹사이트

www.sanofi.com

본부

Paris, Paris, Fra

설립됨

1994

Sanofi is listed in the Health & Allied Services sector of the 유로넥스트 (Euronext) with ticker SAN. The last closing price for Sanofi was 104.84 €. Over the last year, Sanofi shares have traded in a share price range of 85.07 € to 106.14 €.

Sanofi currently has 1,252,640,466 shares in issue. The market capitalisation of Sanofi is 131.33 € billion. Sanofi has a price to earnings ratio (PE ratio) of 23.51.

Communiqué de presse : Sarclisa approuvé au Japon pour le traitement du myélome multiple nouvellement diagnostiqué

Communiqué de presse : Sarclisa approuvé au Japon pour le traitement du myélome multiple nouvellement diagnostiqué Sarclisa approuvé au Japon pour...

Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma

Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Sarclisa approved in Japan for patients with newly...

Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma

Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new...

Communiqué de presse : ECCO 2025 : de nouvelles données sur le duvakitug illustrent son potentiel de meilleur médicament de sa catégorie pour le traitement de la colite ulcéreuse et de la maladie de Crohn

Communiqué de presse : ECCO 2025 : de nouvelles données sur le duvakitug illustrent son potentiel de meilleur médicament de sa catégorie pour le...

Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease

Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease ECCO 2025: new duvakitug...

Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease

ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease New...

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	1.94	1.89416129662	102.42	104.96	102.42	2006971	104.25309044	DE
4	0.5	0.481417292509	103.86	105.58	100.4	1765383	103.95730305	DE
12	12.88	14.0795802361	91.48	105.58	87.5	1663631	98.30849053	DE
26	3.62	3.59340877506	100.74	106.14	87.5	1580670	98.74601554	DE
52	15.4	17.3111510791	88.96	106.14	85.07	1507175	95.07453023	DE
156	11.7	12.626807684	92.66	106.66	76.45	1710088	93.24532402	DE
260	17.96	20.787037037	86.4	106.66	67.65	1922392	89.68207367	DE

SAN - Frequently Asked Questions (FAQ)

What is the current Sanofi share price?

The current share price of Sanofi is 104.36 €

How many Sanofi shares are in issue?

Sanofi has 1,252,640,466 shares in issue

What is the market cap of Sanofi?

The market capitalisation of Sanofi is EUR 131.33B

What is the 1 year trading range for Sanofi share price?

Sanofi has traded in the range of 85.07 € to 106.14 € during the past year

What is the PE ratio of Sanofi?

The price to earnings ratio of Sanofi is 23.51

What is the cash to sales ratio of Sanofi?

The cash to sales ratio of Sanofi is 2.83

What is the reporting currency for Sanofi?

Sanofi reports financial results in EUR

What is the latest annual turnover for Sanofi?

The latest annual turnover of Sanofi is EUR 46.11B

What is the latest annual profit for Sanofi?

The latest annual profit of Sanofi is EUR 5.56B

What is the registered address of Sanofi?

The registered address for Sanofi is 46, AVENUE DE LA GRANDE ARMEE, PARIS, PARIS, 75017

What is the Sanofi website address?

The website address for Sanofi is www.sanofi.com

Which industry sector does Sanofi operate in?

Sanofi operates in the PHARMACEUTICAL PREPARATIONS sector

가장 활성
% 상승자
% 패자

기호	가격	볼륨
ALADOAdomos	0.59 € (180.95%)	162.85k
ALCYBCybergun	0.0002 € (100.00%)	24.87M
DMSBSDiagnostic Medical Systems	0.008 € (77.78%)	50k
ALAMAAMA Corporation PLC	0.233 € (29.81%)	847.73k
LUDSLucibel DS	0.0015 € (25.00%)	13.29k
NEGDSNetmedia Group DS	0.0001 € (-50.00%)	698
ALPCVCerinnov Group	0.618 € (-33.55%)	230.29k
ALKALKALRAY SA	0.641 € (-27.98%)	530.33k
BPOSTBpost SA NV	1.522 € (-26.83%)	6.5M
FRVIAForvia SE	8.442 € (-22.62%)	6.19M
ATOAtos SE	0.0032 € (0.00%)	472.41M
BCPBanco Comercial Portugues SA	0.5366 € (-4.89%)	135.45M
BIOSBiosenic	0.0029 € (-6.45%)	37.45M
ALALOAcheterLouerFR	0.0073 € (0.00%)	36.35M
ALVERVergnet	0.0004 € (0.00%)	33.19M

janice shell 7 분 전

Listening to Trumpty today, or any day, you'd think we were the only country in the world that's helped Ukraine with military stuff since 2022. That's very, very far from the truth. A remarkable number of countries have contributed in various ways. As to the lies Trump's repeatedly told about Europe

DJPele 9 분 전

"Middle of the week"

Well, see you in a month when you make another prediction out of thin air 👋🏽

NWBO

manibiotech 11 분 전

You mean out of 100s of millions of shares she bought with hard earned post tax money ?
Ok thanks

NWBO

MrMike241 12 분 전

Nope, I make judgments based on the source. Trump is everywhere. What he says is what matters. Same for all. I'm not a lemming, are you?

Understand that the reason I post here is singular. In spite of everything happening, my primary concern is protecting the constitution of the Unite

real777mellon 16 분 전

Ours are even more special - that's probably why the feature asset protection, and that exempt list I just found. Lots of reasons why they would put such accounts at Chase Manhattan Bank, N.A. for our property trustee and the account. Wouldn't want to put that account where something was not 100% su

LEHNQ

quester614 20 분 전

WHY does XERI show a different amount for R&D expense at the end of June 2021 compared to the XTI amount if this represents JV funding??
How is the additional R&D money separated into a different classification from the amount of R&D money spent on the JV as CLAIMED by the XTI filing?????????

XERI

littlejohn 24 분 전

putin is genocide promoter that Ukraine

can't afford to trust...

Vance is considered anti-Ukraine and

shouldn't have been in the meeting...

A U.S. Gov't running huge deficits that is

laying off folks and can't afford to fund

janice shell 26 분 전

Legacy media is dead. Mainstream media is dead.

It's all podcasts and social media memes.

The younger generation doesn't care about CNN

It's definitely a new beginning for USA.

Or perhaps a definitive end. Yes, those young people are just b

thecrusher2011 27 분 전

Every single one of you is dangerously misinformed by the liberal media.

It's amazing how little truth you all have been given.

"Ukraine was eventually forced to accept the Budapest Memorandum without robust security guarantees under pressure from the U.S. and Russia, i

toohot 33 분 전

BIEL up 50% at Friday’s close.
‘Nuff said!

BUY $BIEL$

BIEL

Woodpile42 34 분 전

I hope that’s not the case…

VXIT

Investor2014 35 분 전

To me it seems clear!
I agree the speed of which a trial can be executed is very important.
The only new trial recently is the suck it and see one with A3-71.

I can't help thinking that Missling is stringing out new trials with A2-73 until there are some assurances that

AVXL

Jimmy Joe 35 분 전

Probably using it as a tax write off. Complete scam so far.

JPEX

Jimmy Joe 38 분 전

Sucks investors in leaves them with their pants around their ankles.

Known spoofer.

GME

littlejohn 39 분 전

Oil price selloff looking akey fakey now...

https://apnews.com/article/zelenskyy-security-guarantees-trump-meeting-washington-eebdf97b663c2cdc9e51fa346b09591d

Oil stocks that are so beaten down

didn't know about this little change...

Ukrain

GVInvestments 48 분 전

Everyone that I talk to now hate elon. tesla is headed staright to bankcruptcy

TSLA

Jimmy Joe 49 분 전

Already saw Denaro's video.

Hey, do whatcha gotta do. You tend to contradict yourself all the time. Tired~? Sell.

$AMC baby~!

AMC

fuagf 52 분 전

That's the day i'm flying out, the Australian date day, i mean .. ;-)

fuagf 54 분 전

Probably shouldn't have said likely.... just one of those feeeeelingssss .. lol

fuagf 56 분 전

Yeah, it was great, just tangented me is all...

janice shell 56 분 전

lol, 31 March. I just missed being an April Fool.

janice shell 57 분 전

They will do what Trump wants them to do, unless something breaks the spell he's cast on them.

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Sanofi (SAN) 시세

Sanofi (SAN)

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

주요 통계 및 세부정보

Sanofi 정보

SAN 최신 뉴스

Communiqué de presse : Sarclisa approuvé au Japon pour le traitement du myélome multiple nouvellement diagnostiqué

Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma

Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma

Communiqué de presse : ECCO 2025 : de nouvelles données sur le duvakitug illustrent son potentiel de meilleur médicament de sa catégorie pour le traitement de la colite ulcéreuse et de la maladie de Crohn

Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease

Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

Press Release: Sanofi and CD&R sign Opella share purchase agreement

Press Release: Sanofi and CD&R sign Opella share purchase agreement

Communiqué de presse : Sanofi et CD&R annoncent la signature de l’accord d’achat des actions d’Opella

Communiqué de presse : Sarclisa approuvé au Japon pour le traitement du myélome multiple nouvellement diagnostiqué

Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma

Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma

Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease

Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease

Communiqué de presse : ECCO 2025 : de nouvelles données sur le duvakitug illustrent son potentiel de meilleur médicament de sa catégorie pour le traitement de la colite ulcéreuse et de la maladie de Crohn

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

Press Release: Sanofi and CD&R sign Opella share purchase agreement

Communiqué de presse : Sanofi et CD&R annoncent la signature de l’accord d’achat des actions d’Opella

Press Release: Sanofi and CD&R sign Opella share purchase agreement

Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid

Communiqué de presse : La FDA accorde un examen prioritaire à la demande de licence supplémentaire relative au Dupixent pour le traitement ciblé de la pemphigoïde bulleuse

SAN - Frequently Asked Questions (FAQ)

이동자

토론

최근 히스토리

회사 소개

사업

Popular

앱 받기

광고 제거